Complete Synthetic Vaccine with Built-In Adjuvant,
Abstract
In the conventional approach to synthetic vaccines, peptide antigens coupled to a high molecular weight protein in combination with adjuvant such as complete Freund's adjuvant are administrated as a heterogeneous mixture. Unfortunately, such a preparation is not suitable for human use due to undesirable side effects. To overcome this deficiency that hampers the progress to synthetic vaccines, we investigated a novel approach to develop a complete peptide-based synthetic vaccine with a built-in adjuvant. We covalently linked to a multiple antigen peptide (MAP) a potent B cell and macrophage activator, tripalmitoyl-S glyceryl cysteine (P3C) (2.3). Moreover, we also used this new construc liposomes which have been shown to improve the immune response. We chose as a model the peptide which is part of the principal neutralizing determinant located in the V loop of gp120 of the human immunodeficiency virus type I, III strain.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1992
- Accession Number
- ADP008555
Entities
People
- Bernardetta Nardelli
- Denise R. Shiu
- James P. Tam
- Jean-philippe Defoort
- Wolin Huang
Organizations
- The Rockefeller University